Unrelated hematopoietic stem cell transplantation (HSCT) is a recognized therapy for hematological diseases and over 8 million HLA-typed donors are ready to donate. Increased international exchanges and rapid requests through the Bone Marrow Donor Worldwide (BMDW) ask for standardized quality assurance. Since no such standards have been established to date, we tested a pilot program in order to evaluate donor availability and quality of HLA typing of the Swiss Registry.The 18500 donors of the registry have been analyzed by serology for HLA-AB and by molecular typing for HLA-DR. Through three successive annual quality control (QC) exercises, a total of 114 donor requests were sent to 13 blood transfusion centers responsible for donor recruitment asking for a blood sample. Donors were randomly selected according to recruitment periods (1988-1993; 1994-1997; 1998-2000), and to homozygosity for HLA-A and/or -B antigens. An additional 80 frozen blood samples from the repository corresponding to the three periods (n ¼ 26) and to the 2001 period (n ¼ 54) were also included in the HLA study. HLA-AB typings were done by polymerase chain reaction-sequence specific primers (PCR-SSP) and all discrepancies were retyped. The results showed that 79 samples provided by 69.3% of the requested donors were received within 14 days, and 19 samples (16.7%) were received in 414 days. Altogether, an 86% rate of donor availability was observed, independent of the recruitment period. Among the requested donors, 16 (14%) were not available: for medical reasons (two), for personal reasons (eight), for loss (one), and for an unknown reason (five). The HLA-A/B DNA typing results of 166 homozygous and 12 heterozygous blood samples showed that 437/439 (99.5%) of the assigned A/B antigens were correct.
Unrelated hematopoietic stem cell transplantation (HSCT) is a recognized therapy for hematological diseases and over 8 million HLA-typed donors are ready to donate. Increased international exchanges and rapid requests through the Bone Marrow Donor Worldwide (BMDW) ask for standardized quality assurance. Since no such standards have been established to date, we tested a pilot program in order to evaluate donor availability and quality of HLA typing of the Swiss Registry.The 18500 donors of the registry have been analyzed by serology for HLA-AB and by molecular typing for HLA-DR. Through three successive annual quality control (QC) exercises, a total of 114 donor requests were sent to 13 blood transfusion centers responsible for donor recruitment asking for a blood sample. Donors were randomly selected according to recruitment periods (1988-1993; 1994-1997; 1998-2000) , and to homozygosity for HLA-A and/or -B antigens. An additional 80 frozen blood samples from the repository corresponding to the three periods (n ¼ 26) and to the 2001 period (n ¼ 54) were also included in the HLA study. HLA-AB typings were done by polymerase chain reaction-sequence specific primers (PCR-SSP) and all discrepancies were retyped. The results showed that 79 samples provided by 69.3% of the requested donors were received within 14 days, and 19 samples (16.7%) were received in 414 days. Altogether, an 86% rate of donor availability was observed, independent of the recruitment period. Among the requested donors, 16 (14%) were not available: for medical reasons (two), for personal reasons (eight), for loss (one), and for an unknown reason (five). The HLA-A/B DNA typing results of 166 homozygous and 12 heterozygous blood samples showed that 437/439 (99.5%) of the assigned A/B antigens were correct.
However in 36/178 donors (20.2%) an HLA-A or -B antigen had been missed (34 donors) or misassigned (two donors) by serology, with a decreasing discrepancy rate of 30% (1988) (1989) (1990) (1991) (1992) (1993) to 18.5% in 2001. Assuming that HLA-A or -B homozygotes are found in 10-15% of the donors and that correct assignments have been observed in nearly 100% of the donors, an overall error rate of 4-5% would be expected for the national registry HLA-AB typing. These data show that standardized quality control for donor availability and HLA typing is feasible, and we propose that this model could be applied to the registries participating in bone marrow donor worldwide. Bone Marrow Transplantation (2003) 32, 623-627. doi:10.1038/sj.bmt.1704229 Keywords: bone marrow donor registry; quality control; donor availability; HLA serology; typing discrepancies; homozygotes Allogeneic hematopoietic stem cell transplantation (HSCT) is a recognized curative therapy for a number of hematological diseases and one-third of allogeneic transplants are now performed with HSC from an unrelated donor. 1 More than 8 million HLA-typed donors from 51 bone marrow and 29 cord blood donor registries are available through bone marrow donor worldwide (BMDW), allowing optimal selection of the best compatible donor. Due to a continuous increase in donor recruitment by the national registries, the probability of finding a HLA-ABDR matched donor at the initial search through BMDW has risen from 15% in 1987 to 85-95% in 2001 [2] [3] [4] (M Oudshoorn, personal communication). Increasing international exchange and rapid requests ask for standardized quality assurance. Since donor recruitment is time consuming and because of the high cost of the HLA typing, it seems particularly relevant to evaluate these parameters in order to optimize the allocation of resources, taking into account that only 10 À2 -10 À3 donors will eventually be called. Relatively few data are available that allow a precise estimate of donor availability and HLA typing quality of the donor pool. One simple approach is to calculate the success rate at obtaining a confirmatory typing (CT) sample and to compute the overall rate of discordant typings, or to randomly retype stored material from the donor pool. Unfortunately, very few registries have this information. 3, 5, 6 The limitations of HLA-AB serology have been first analyzed in the organ transplant field with 5-25% discrepancy rates in class I typings. [7] [8] [9] [10] In particular, a 25% discrepancy rate for HLA-B serological homozygotes has been reported. 9 More recently, a combined serology/polymerase chain reaction-sequence specific primers (PCR-SSP) analysis of donors from the Tobias Registry (Sweden) showed an overall 3% discrepancy rate, but among homozygotes, 12% for HLA-A and 19% for HLA-B discrepancies, respectively, were observed. 11 The largest study group of donors typed both by serology (performed in 1993-1997) and by PCR-SSOP hybridization or PCR-SSP concerns 440 000 non-Caucasoid donors from National Marrow Donor Program (NMDP). 12 An overall discrepancy rate of 24% has been reported, 8% for HLA-A, 13% for HLA-B, and 3% for both HLA-A and -B.
12 Similar rates were also reported very recently by a quality control (QC) analysis of the laboratories contracted by the NMDP Registry. 13 The Swiss Bone Marrow Donor Registry, founded in 1988, has now registered over 18 500 HLA-typed donors, who have been recruited by 13 regional blood transfusion centers.
14 The Registry coordinates all unrelated HSCT donor searches for patients to be transplanted in the country and also provides donors for patients abroad through a close collaboration with BMDW. The recruited donors are typed for HLA-AB by serology in the HLA laboratories linked to the blood transfusion centers, and for HLA-DR by DNA techniques in the National Reference Laboratory for Histocompatibility (LNRH). The donors recruited by centers that are not linked to an HLA typing laboratory are also typed by the LNRH for HLA-AB. Since 1994, the LNRH also stores a 1-ml blood sample from each donor for further HLA testing by DNA methods if required. For example, high-resolution molecular typing (allele-level, e.g. DRB1*0401) can be rapidly performed in case the donor is selected on the basis of ABDR compatibility as determined at the generic level (e.g. DRB1*04).
Extending a previous study, 4 more recent confirmatory typing of 41200 donors provided through BMDW for searches run from 1995 to 2001 revealed that 11% of the recruited donors were incompatible for HLA-ABDR at the generic level, due to incorrect antigen assignments, or to missing split antigens (e.g. A9, B40, DR2). This implies that approximately one out of 10 donors is inappropriately called up for a confirmatory typing (CT) test. This experience prompted us to test the feasability of a quality system evaluating two main factors: donor availability and quality of the HLA typing performed in the different laboratories of the country.
Donors and methods

Study design
Blood sample requests were sent by the Swiss Bone Marrow Donor Registry to 13 regional blood transfusion centers responsible for donor recruitment and follow-up. Each letter mentioned the purpose of the QC exercise and requested a blood sample from the donors to be sent to the LNRH within 14 days. Donors were randomly selected by the LNRH according to three different recruitment periods (1988-1993, 1994-1997, 1998-2000) , and to the presence of homozygosity at HLA-A and/or -B loci for the 2000 and 2001 QC exercises and to the presence of A2, A28, A19, or B15 antigens (in homozygous or heterozygous combinations) for the 2002 QC exercise. In order to extend our evaluation of HLA-AB serology, an additional set of 80 samples, originally obtained from all centers, were randomly selected from the blood sample repository at the LNRH. A total of 26 samples were selected according to the three recruitment periods, and 54 samples were selected from the latest 2001 period, in order to obtain a most recent evaluation of the serological typing trays.
Donor availability
Donor availability was calculated based on the 114 requests sent by the Registry to the blood transfusion centers. Time was computed from the date of the letter until reception of the blood sample by the LNRH. Whenever possible the reason for unavailability of a donor was recorded by the recruiting center.
HLA typing discrepancies
All samples had been previously typed by serology (Biotest AB120, and additional trays whenever required) at the time of donor registration (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) . For the QC protocol, all samples were retyped by PCR-SSP (Dynal, Genovision or Biotest) at the generic level. HLA-DR typing was performed by reverse PCR-SSOP hybridization (bioMe´r-ieux) on microtiter plate.
Discrepancies were defined as follows:
(1) a serological blank with an assigned specificity by DNA typing (e.g. B7 by serology, B*07, B*1510 by DNA typing); (2) an antigen assigned by serology, but not detected by DNA typing (e.g. A2, A28 by serology, A*02 by DNA typing); (3) an incorrect split antigen (e.g. A30 by serology, A*31 by DNA typing); (4) a serotype misassignment (e.g. B35 by serology, B*1501 (B62) by DNA typing).
All discordant results were verified by a third DNA test, using a different typing kit, whenever available. When DNA generic typing allowed to detect split antigen specificities, whereas serology only reported the broad antigen, this was considered as concordant (e.g. A19 by serology, A*30 by DNA typing).
Results
Availability of the donors
All 13 recruitment centers participated in this pilot study over the whole 3-year period. A total of 114 requests were sent to the 13 regional blood transfusion centers explaining the aims of the QC exercise and asking for a 20-ml blood sample from the donors within 14 days. All donors were randomly selected according to the criteria indicated in Donors and Methods. The results in Table 1 show that 79 samples (69.3%) were received in the LNRH within 14 days, while 19 donors (16.7%) were mobilized within 2-8 weeks. In all, 16 donors (14.0%) were not available, either for medical (two), personal (eight), unknown (five) reasons, or were lost to follow-up (one). Thus, an overall eligibility for calling of 86% was determined through this 3-year QC. This rate is in accordance with the ratio of donors from the Swiss Registry who could be mobilized for a CT blood sample donation. Indeed CT samples were sent in 88.3, 85.6 and 80.0% of the requests in 1999, 2000, and 2001, respectively. The number of donors who were not eligible for medical reasons increased from 7.7% in 1999 to 14.0% in 2001, while the ratio of donors who did not donate for personal reasons or because they were abroad remained constant by 4-6% (G Nicoloso de Faveri and M Kern, unpublished observation).
HLA discrepancies between serology and DNA typing
By combining 98 blood samples received after sending the 114 requests for annual QC exercises with 80 frozen blood samples stored at the LNRH, a total of 178 donor samples initially typed for HLA-AB by serology at the recruitment time were verified by DNA typing (Table 2) antigens assigned by serology, 437 (99.5%) were confirmed by DNA typing, even though in a number of cases PCR-SSP allowed to define serological splits more precisely. A19 splits could thus be further characterized as were A28, B5, or B17 splits. However, a discrepancy was observed in 38 (20.2%) samples (Table 2) , 36 resulting from the identification by PCR-SSP of antigens missed by serology, and two resulting from misassignment of A28 in A2/A28 heterozygotes. The discrepancy rates decreased from 30% (period 1988-1993) to 18.6% (period 1994-1997). Since then it has not decreased further significantly: 14.6% in 1998-2000 and 18.5% in 2001 (not shown). It is noteworthy that 32.3% of the missed antigens belonged to the A19 group and that 20.5% concerned the B70 antigens (Table 3) . Also HLA-B46, supposedly extremely rare in Caucasian populations, was identified in two of the 36 donors with discrepant typing results. PCR-SSP typing for HLA-AB confirmed split antigens of the A9, A10, A19, B5, B12, B15, B16, B17, B21, B22, B40 serotypes in all donors (n ¼ 81) where serological splits had been assigned. In 35 donors, broad antigens could be split by DNA typing into A24(1), A25(1), A29(1), A30(3), A30/A31(1), A32(1), A33(1), A68(17), B51(2), B55/B56(1), B57/B58(1), and B58(1), B60(1), B62(2), and B64(1) (not shown).
From the first two QC exercises, HLA-DR results were verified for 41 donors (24 heterozygous and 17 homozygous donors). Of a total of 64 reported antigens (DR generic or 2-digit typing), 100% were correctly assigned by PCR-SSOP hybridization, and one single DR allele (DRB1*04) had been missed by DNA typing in the 1988-1993 period (2.4% of the donors). 
Discussion
This paper describes a simple QC scheme allowing determination of donor availability and quality of HLA-AB serological typing of a national registry. The 86% rate of donor availability determined throughout the three QC exercises is in accordance with the 80% rate of donors effectively mobilized by the Swiss Registry for a CT in 2001 (85.6% in 2000). This rate is also in line with the 80% availability rate reported for the Welsh Registry, 5 and with the 75% rate computed for searches led for Dutch patients on BMDW (M Oudshoorn, personal communication). There was no difference with regard to the period of recruitment, that is, donors registered more than 8-10 years ago were not more difficult to mobilize than recently registered donors. The HLA typing results were, perhaps, less expected, since we observed that the standard microlymphocytotoxicity assay for HLA-AB typing was missing a class I antigen in 20% of homozygous donors, although 499% of the assigned antigens were correct. Here, a clear-cut difference was observed between the error rate in early (30% in 1988-1993) vs recent (18% in 2001) serological typings, most likely resulting from improved typing reagents. It is important to note that the 20% average discrepancy rate does not represent the overall error rate of the registry. Taking into account the fact that correct antigen assignments were observed in practically all heterozygotes, and assuming a 20-25% rate for combined HLA-A and -B homozygotes, one can predict an overall 4-5% error rate for HLA class I of the Swiss Registry. This estimate is very close to that reported for the Swedish Registry. 10 As also observed by previous investigators, [9] [10] [11] [12] the missed antigens belong preferentially to the A19 and B70 groups and are notoriously difficult to define because of lack of monospecific antisera. The DNA retyping results therefore show that systematic verification by molecular typing of HLA-AB homozygous samples will significantly improve the histocompatibility records of the Registry. The data presented in this paper show that a simple quality assurance system is feasible and is readily accepted by recruiting centers and donors, and we suggest that this model, based on a limited number of blood sample requests and focused on distinct recruitment periods and potential HLA typing problems, could also apply to the registries participating in BMDW. The organisation of such a QC scheme (e.g. number of samples per recruitment period, selection of the donors) would rely on national registries which will then report their results to the World Marrow Donor Association Quality Assurance working group. In order to allow useful comparisons, the time frame for donor recruitment (15 or 30 days) and the technique used for ABDR antigen assignments (serology or DNA typing) must be well defined. An international comparison, on an anonymous basis, of donor availability rates as a function of recruitment periods, and of HLA typing quality, should be of use for each participating registry. Antigens misassigned (n ¼ 2) A2, A28 by serology, A*02,-by DNA typing
